<DOC>
	<DOCNO>NCT02070718</DOCNO>
	<brief_summary>Studies suggest kappa agonist ( KA ) peripherally restrict kappa agonist ( PRKAs ) may affect thermoregulation . This pilot study aim establish proof concept regard efficacy oral kappa agonist ( KA ) treatment menopausal hot flash .</brief_summary>
	<brief_title>Effects Kappa Agonist Hot Flashes Menopausal Women</brief_title>
	<detailed_description>To establish proof concept regard efficacy oral kappa agonist ( KA ) , Pentazocine/ Naloxone 50/0.5 mg , treatment menopausal hot flash . To gather data support future proposal study safety efficacy PRKA , type KA , amelioration menopausal hot flash .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Pentazocine</mesh_term>
	<criteria>1 . Healthy woman 4560 year age ; 12 month amenorrhea 2 . Documentation &gt; 8 moderate severe , daily hot flash one week baseline monitoring use daily diary 3 . Availability family member friend drive participant home follow clinic visit 1 . Use hormonal prescription medication supplement vasomotor symptom ( VMS ) 2 . Use narcotics 3 . Use SSRI ( selective serotonin reuptake inhibitor ) /SNRI ( serotoninnorepinephrine reuptake inhibitor ) , gabapentin , MAOI ( monoamine oxidase inhibitor ) , antiepileptic , sedatives 4 . History polycystic ovarian syndrome hirsutism 5 . Current history depression 6 . Any chronic acute medical illness include renal , hepatic , pulmonary disease , seizures 7 . Substance abuse 8 . Severe corn allergy 9 . Known allergic reaction pentazocine naloxone 10 . Presence condition abnormality opinion Investigator would compromise safety patient quality data 11 . Hysterectomy 12 . Use anticholinergic medication 13 . Lactating pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>hot flash</keyword>
	<keyword>menopause</keyword>
	<keyword>kappa agonist</keyword>
</DOC>